Carvedilol Tablets — Class II drug recall D-0216-2025
Ongoing recall by Glenmark Pharmaceuticals Inc., USA, reported 2025-02-12, distributed nationwide. CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended
| Recall number | D-0216-2025 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ, United States |
| Recall initiated | 2025-01-22 |
| Classified | 2025-02-03 |
| Reported by FDA | 2025-02-12 |
| Distributed | Nationwide (US) |
| Reason classes | cgmp, specification failure |
| NDC | 68462-0162, 68462-0162-01, 68462-0162-05, 68462-0162-10, 68462-0162-18, 68462-0162-60, 68462-0163, 68462-0163-01, 68462-0163-05, 68462-0163-10, 68462-0163-18, 68462-0163-60, 68462-0164, 68462-0164-01, 68462-0164-05, 68462-0164-10, 68462-0164-18, 68462-0164-60, 68462-0165, 68462-0165-01, 68462-0165-05, 68462-0165-10, 68462-0165-18, 68462-0165-60 |
| Expiration dates | 2025-02, 2025-03, 2025-04, 2025-05, 2025-06, 2025-07, 2025-09, 2025-10, 2026-01, 2026-02 |
Product
Carvedilol Tablets, USP, 12.5 mg, Rx only, a)500 Tablets, NDC 68462-164-05; b) 100 Tablets, NDC 68462-164-01, Manufactured for Glenmark Pharmaceuticals, NJ.
Reason for recall
CGMP Deviations:N-Nitroso Carvedilol I impurity (NNCI-I) were found to be failing per current FDA recommended limit.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0216-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.